Claims for Patent: 7,455,842

Summary for Patent: 7,455,842

Title:	Chimeric West Nile viruses and uses thereof
Abstract:	A chimeric West Nile live virus comprised of the NY99 and WN1415 strains and an infectious DNA recombinant construct encoding for the chimeric virus are provided, as well as immunogenic compositions and their method of use.
Inventor(s):	Yamshchikov; Vladimir F. (Olathe, KS)
Assignee:	University of Kansas (Lawrence, KS)
Application Number:	11/294,178
Patent Claims:	1. A recombinant genetic construct, adapted to encode a full-length West Nile viral genome, comprising a nucleic acid region encoding a structural protein of a first West Nile virus and a nucleic acid region encoding a non-structural protein of a second West Nile virus, wherein said second West Nile virus is a different virus from said first West Nile virus. 2. The recombinant genetic construct of claim 1 wherein said first West Nile virus and said second West Nile virus are independently selected from the group consisting of strains NY99 and WN1415. 3. The recombinant genetic construct of claim 1 wherein the nucleic acid region encoding a structural protein of said first West Nile virus encodes the premembrane (prM) and envelope (E) proteins of the NY99 virus and the nucleic acid region encoding a non-structural protein of said second West Nile virus encodes the NS 1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 proteins of the WN1415 virus. 4. The recombinant genetic construct of claim 3 wherein the nucleic acid region encoding a structural protein of said first West Nile virus also encodes the capsid (C) protein of the NY99 virus. 5. The recombinant genetic construct of claim 1 wherein the nucleic acid region encoding a structural protein of said first West Nile virus encodes the capsid (C), premembrane (prM) and envelope (E) proteins of the WN1415 virus and the nucleic acid region encoding a non-structural protein of said second West Nile virus encodes the NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 proteins of the NY99 virus. 6. The recombinant genetic construct of claim 1 wherein said nucleic acid region encoding a structural protein of said first West Nile virus is derived from a more virulent West Nile virus than said nucleic acid region encoding a non-structural protein of said second West Nile virus, which is less virulent. 7. The recombinant genetic construct of claim 1 wherein the nucleic acid region encoding a structural protein encodes an E protein that is not glycosylated or contains a mutated glycosylation site. 8. The recombinant genetic construct of claim 1 further comprising at least one open reading frame interrupting intron downstream from the first occurrence of AUG in the cluster of in-frame AUG codons occurring at the end of the E gene. 9. The recombinant genetic construct of claim 8 wherein said at least one open reading frame interrupting intron is located at position 2210 or 2384 of the West Nile genome. 10. The recombinant genetic construct of claim 1 further comprising at least one open reading frame interrupting intron in the area encompassing the 3' end of the NS1 gene and 5' end of the NS2A gene. 11. The recombinant genetic construct of claim 1 further comprising a vector. 12. The recombinant genetic construct of claim 11 wherein said vector is a plasmid. 13. The recombinant genetic construct of claim 12 wherein said plasmid comprises DNA encoding an infectious (+) RNA molecule under the control of a eukaryotic promoter. 14. The recombinant genetic construct of claim 13 wherein said eukaryotic promoter comprises a CMV promoter. 15. A host cell stably or transiently transfected with the recombinant genetic construct of claim 1. 16. An infectious West Nile virus comprising a full-length West Nile viral genome, comprising a nucleic acid region encoding a structural protein of a first West Nile virus and a nucleic acid region encoding a non-structural protein of a second West Nile virus, wherein said second West Nile virus is a different virus from said first West Nile virus. 17. An immunogenic composition against West Nile virus comprising a therapeutically effective amount of the recombinant genetic construct of claim 1 and a pharmaceutically acceptable carrier. 18. A method of immunizing a subject against West Nile virus comprising the step of administering to a subject the immunogenic composition of claim 17. 19. The recombinant genetic construct of claim 1 wherein the nucleic acid region encoding a structural protein of said first West Nile virus encodes the premembrane (prM) and envelope (E) proteins of a first West Nile virus and the nucleic acid region encoding a non-structural protein of said second West Nile virus encodes the NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 proteins of a second West Nile virus, and further comprising at least one open reading frame interrupting intron downstream from the first occurrence of AUG in the cluster of in-frame AUG codons occurring at the end of the E gene, at least one intron is located at position 2210, 2384, or 3472 of the West Nile genome. 20. The recombinant genetic construct of claim 19 wherein said first West Nile virus is the NY99 virus, and said second West Nile virus is the WN1415 virus. 21. The recombinant genetic construct of claim 8 further comprising at least one additional open reading frame interrupting intron in the area encompassing the 3' end of the NS1 gene and 5' end of the NS2A gene. 22. The recombinant genetic construct of claim 9 further comprising at least one additional open reading frame interrupting intron at position 3472 of West Nile Virus genome. 23. The recombinant genetic construct of claim 10 wherein the at least one open reading frame interrupting intron at position 3472 of West Nile Virus genome.

Details for Patent 7,455,842

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26